Horizon Pharma continues to see FY18 revenue $1.17B-$1.2B, consensus $1.17B
The company increased its full-year 2018 adjusted EBITDA guidance to a range of $400M-$420M, from $390M-$415M. The company continues to project full-year 2018 net sales growth for KRYSTEXXA of more than 65%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.